| Dr Maria A Guglielmo, MD | |
|
120 Centerville Rd, Warwick, RI 02886-4336 | |
| (401) 738-3730 | |
| (401) 738-3777 |
| Full Name | Dr Maria A Guglielmo |
|---|---|
| Gender | Female |
| Speciality | Neurosurgery |
| Experience | 32 Years |
| Location | 120 Centerville Rd, Warwick, Rhode Island |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063504512 | NPI | - | NPPES |
| 9004550 | Medicaid | RI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | MD11912 (Rhode Island) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Newport Hospital | Newport, RI | Hospital |
| Rhode Island Hospital | Providence, RI | Hospital |
| Kent County Memorial Hospital | Warwick, RI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lifespan Physician Group Inc | 2567455082 | 631 |
| Newport Hospital | 0042111437 | 34 |
| Rhode Island Hospital | 8921900044 | 303 |
News Archive
Modern Negative Pressure Wound Therapy (NPWT) has been in practice since the late 1970's when plastic surgeon Dr. Paul Svedman began treating patients. It is estimated that over half a million patients in the United States receive NPWT every year, but that millions more would benefit from the therapy if it were more accessible.
A recent survey of 202 neonatologists and pediatricians, which examined current attitudes and practices when caring for the specialized health needs of preterm infants, revealed that most respondents (70 percent) feel the United States' healthcare system does not place enough emphasis on or dedicate enough resources to preventive healthcare for preemies.
Twelve investigators have received grants totaling $5 million over two years to lead high-impact, innovative studies of food allergy, a significant public health concern.
According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the emerging market for neurovascular embolectomy devices for the treatment of acute ischemic stroke is poised for healthy yet conservative growth of close to 15% annually in Europe over the next 5 years.
IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that its IRIS Molecular Diagnostics (IMD) subsidiary has submitted a 510(k) pre-market notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for NADiA®ProsVue™, a prostate cancer prognostic test. The test is designed to help physicians identify patients at low risk of cancer recurrence post radical prostatectomy.
› Verified 8 days ago
| Entity Name | Newport Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063632180 PECOS PAC ID: 0042111437 Enrollment ID: O20040422000696 |
News Archive
Modern Negative Pressure Wound Therapy (NPWT) has been in practice since the late 1970's when plastic surgeon Dr. Paul Svedman began treating patients. It is estimated that over half a million patients in the United States receive NPWT every year, but that millions more would benefit from the therapy if it were more accessible.
A recent survey of 202 neonatologists and pediatricians, which examined current attitudes and practices when caring for the specialized health needs of preterm infants, revealed that most respondents (70 percent) feel the United States' healthcare system does not place enough emphasis on or dedicate enough resources to preventive healthcare for preemies.
Twelve investigators have received grants totaling $5 million over two years to lead high-impact, innovative studies of food allergy, a significant public health concern.
According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the emerging market for neurovascular embolectomy devices for the treatment of acute ischemic stroke is poised for healthy yet conservative growth of close to 15% annually in Europe over the next 5 years.
IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that its IRIS Molecular Diagnostics (IMD) subsidiary has submitted a 510(k) pre-market notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for NADiA®ProsVue™, a prostate cancer prognostic test. The test is designed to help physicians identify patients at low risk of cancer recurrence post radical prostatectomy.
› Verified 8 days ago
| Entity Name | Lifespan Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407116643 PECOS PAC ID: 2567455082 Enrollment ID: O20121029000368 |
News Archive
Modern Negative Pressure Wound Therapy (NPWT) has been in practice since the late 1970's when plastic surgeon Dr. Paul Svedman began treating patients. It is estimated that over half a million patients in the United States receive NPWT every year, but that millions more would benefit from the therapy if it were more accessible.
A recent survey of 202 neonatologists and pediatricians, which examined current attitudes and practices when caring for the specialized health needs of preterm infants, revealed that most respondents (70 percent) feel the United States' healthcare system does not place enough emphasis on or dedicate enough resources to preventive healthcare for preemies.
Twelve investigators have received grants totaling $5 million over two years to lead high-impact, innovative studies of food allergy, a significant public health concern.
According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the emerging market for neurovascular embolectomy devices for the treatment of acute ischemic stroke is poised for healthy yet conservative growth of close to 15% annually in Europe over the next 5 years.
IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that its IRIS Molecular Diagnostics (IMD) subsidiary has submitted a 510(k) pre-market notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for NADiA®ProsVue™, a prostate cancer prognostic test. The test is designed to help physicians identify patients at low risk of cancer recurrence post radical prostatectomy.
› Verified 8 days ago
| Entity Name | Rhode Island Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154537520 PECOS PAC ID: 8921900044 Enrollment ID: O20141017000105 |
News Archive
Modern Negative Pressure Wound Therapy (NPWT) has been in practice since the late 1970's when plastic surgeon Dr. Paul Svedman began treating patients. It is estimated that over half a million patients in the United States receive NPWT every year, but that millions more would benefit from the therapy if it were more accessible.
A recent survey of 202 neonatologists and pediatricians, which examined current attitudes and practices when caring for the specialized health needs of preterm infants, revealed that most respondents (70 percent) feel the United States' healthcare system does not place enough emphasis on or dedicate enough resources to preventive healthcare for preemies.
Twelve investigators have received grants totaling $5 million over two years to lead high-impact, innovative studies of food allergy, a significant public health concern.
According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the emerging market for neurovascular embolectomy devices for the treatment of acute ischemic stroke is poised for healthy yet conservative growth of close to 15% annually in Europe over the next 5 years.
IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that its IRIS Molecular Diagnostics (IMD) subsidiary has submitted a 510(k) pre-market notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for NADiA®ProsVue™, a prostate cancer prognostic test. The test is designed to help physicians identify patients at low risk of cancer recurrence post radical prostatectomy.
› Verified 8 days ago
| Entity Name | Orthopedics Rhode Island Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407231293 PECOS PAC ID: 7012225907 Enrollment ID: O20150925001150 |
News Archive
Modern Negative Pressure Wound Therapy (NPWT) has been in practice since the late 1970's when plastic surgeon Dr. Paul Svedman began treating patients. It is estimated that over half a million patients in the United States receive NPWT every year, but that millions more would benefit from the therapy if it were more accessible.
A recent survey of 202 neonatologists and pediatricians, which examined current attitudes and practices when caring for the specialized health needs of preterm infants, revealed that most respondents (70 percent) feel the United States' healthcare system does not place enough emphasis on or dedicate enough resources to preventive healthcare for preemies.
Twelve investigators have received grants totaling $5 million over two years to lead high-impact, innovative studies of food allergy, a significant public health concern.
According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the emerging market for neurovascular embolectomy devices for the treatment of acute ischemic stroke is poised for healthy yet conservative growth of close to 15% annually in Europe over the next 5 years.
IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that its IRIS Molecular Diagnostics (IMD) subsidiary has submitted a 510(k) pre-market notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for NADiA®ProsVue™, a prostate cancer prognostic test. The test is designed to help physicians identify patients at low risk of cancer recurrence post radical prostatectomy.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Maria A Guglielmo, MD 120 Centerville Rd, Warwick, RI 02886-4336 Ph: () - | Dr Maria A Guglielmo, MD 120 Centerville Rd, Warwick, RI 02886-4336 Ph: (401) 738-3730 |
News Archive
Modern Negative Pressure Wound Therapy (NPWT) has been in practice since the late 1970's when plastic surgeon Dr. Paul Svedman began treating patients. It is estimated that over half a million patients in the United States receive NPWT every year, but that millions more would benefit from the therapy if it were more accessible.
A recent survey of 202 neonatologists and pediatricians, which examined current attitudes and practices when caring for the specialized health needs of preterm infants, revealed that most respondents (70 percent) feel the United States' healthcare system does not place enough emphasis on or dedicate enough resources to preventive healthcare for preemies.
Twelve investigators have received grants totaling $5 million over two years to lead high-impact, innovative studies of food allergy, a significant public health concern.
According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the emerging market for neurovascular embolectomy devices for the treatment of acute ischemic stroke is poised for healthy yet conservative growth of close to 15% annually in Europe over the next 5 years.
IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that its IRIS Molecular Diagnostics (IMD) subsidiary has submitted a 510(k) pre-market notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for NADiA®ProsVue™, a prostate cancer prognostic test. The test is designed to help physicians identify patients at low risk of cancer recurrence post radical prostatectomy.
› Verified 8 days ago
Henry E Laurelli, M.D. Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 176 Toll Gate Rd, Suite 203, Warwick, RI 02886 Phone: 401-739-4988 Fax: 401-739-4739 |